Image

Global Immuno-Oncology (IO) Market - Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Feb 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Immuno-Oncology (IO) Market, By Type (Immune Cell Therapy (CAR-T), Monoclonal Antibodies, Checkpoint Inhibitors, Cytokines, Cancer Vaccines, Others), Targets (LAG-3, anti-CTLA-4, MAGE-A3, VEGF, HDAC, STING, TIM-3, TGF-Beta, OX40, Others), Indication (Malignant Tumors, Benign Tumors, Others), End Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of the Middle East and Africa) Industry Trends and Forecast to 2029.

Immuno-Oncology (IO) Market

Market Analysis and Insights Global Immuno-Oncology (IO) Market

The immuno-oncology (IO) market is expected to witness market growth at a rate of 8.90% in the forecast period of 2022 to 2029. Data Bridge Market Research report on the immuno-oncology (IO) market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The rise in the prevalence of cancer related disorders around the world is escalating the growth of the immuno-oncology (IO) market.

Immuno-oncology (IO) is referred to as the treatment of several cancers with the utilization of bispecific-antibodies, cancer vaccines, cell therapies, checkpoint modulators and oncolytic viruses.

Major factors that are expected to boost the growth of the immuno-oncology (IO) market in the forecast period are the rise in the research and development in the cancer immunotherapy. Furthermore, the introduction of developed treatment options that are more effective and efficient is further anticipated to propel the growth of the immuno-oncology (IO) market. Moreover, the rise in the competitive rivalry is further estimated to cushion the growth of the immuno-oncology (IO) market. On the other hand, the strict FDA guidelines for the drug approval of new drug is further projected to impede the growth of the immuno-oncology (IO) market in the timeline period.

In addition, the augmented development in the treatment of cancer and increase in the population with immune system diseases around the world will further provide potential opportunities for the growth of the immuno-oncology (IO) market in the coming years. However, the adverse effect after the treatment might further challenge the growth of the immuno-oncology (IO) market in the near future.

The immuno-oncology (IO) market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the immuno-oncology (IO) market scenario, contact Data bridge market research for an Analyst Brief, Our team will help you create a revenue impact solution to achieve your desired goal.

Global Immuno-Oncology (IO) Market Scope and Market Size

The immuno-oncology (IO) market is segmented on the basis of type, target, indication, end users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of type, the immuno-oncology (IO) market is segmented into immune cell therapy (CAR-T), monoclonal antibodies, checkpoint inhibitors, cytokines, cancer vaccines and others.
  • On the basis of target, the immuno-oncology (IO) market is segmented into LAG-3, anti-CTLA-4, MAGE-A3, VEGF, HDAC, STING, TIM-3, TGF-Beta, OX40, Others.
  • On the basis of indication, the immuno-oncology (IO) market is segmented into malignant tumors, benign tumors and others.
  • On the basis of end users, the Immuno-Oncology (IO) market is segmented into hospitals, specialty clinics and others.
  • On the basis of distribution channel, the immuno-oncology (IO) market is segmented into hospitals, specialty clinics and others.

Immuno-Oncology (IO) Market Country Level Analysis

The immuno-oncology (IO) market is analyzed, and market size information is provided by country, type, target, indication, end users and distribution channel as referenced above.

The countries covered in the immuno-oncology (IO) market report are the U.S., Canada, and Mexico in North America, Peru, Brazil, Argentina, and the rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, rest of the Middle East and Africa (MEA) as a part of the Middle East and Africa (MEA).

North America dominates the immuno-oncology (IO) market due to the rise in the incidence of the disease. Furthermore, the growing ease of access to modern therapeutics will further boost the growth of the immuno-oncology (IO) market in the region during the forecast period. Asia-Pacific is projected to observe significant amount of growth in the growing favorable growth rate in cancer immunotherapy adoption. Moreover, the rise in the incidence of the disease and in turn, increasing mortality rate is further anticipated to propel the growth of the immuno-oncology (IO) market in the region in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The immuno-oncology (IO) market also provides you with detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to the market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Immuno-Oncology (IO) Market Share Analysis

The immuno-oncology (IO) market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to the immuno-oncology (IO) market.

Some of the major players operating in the immuno-oncology (IO) market are Bristol Myers Squibb Company, Novartis AG, F. Hoffmann-LA Roche Ltd., Merck & Co., Inc., Regeneron Pharmaceuticals, GlaxoSmithKline Plc., Eli Lilly and Company, Fresenius Kabi AG, Pfizer Inc., AbbVie Inc., Genentech Inc., Sanofi, and AstraZeneca PLC among others.

Customization Available : Global Immuno-Oncology (IO) Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market, and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions